UroGen hands anti-CTLA-4 drug back to Agenus after being unimpressed with phase 1 data
UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding phase 1 data for the bladder cancer drug didn’t reach the benchmark for further development. New Jersey-based UroGen forked…